Astellas Pharma Inc.

OTC: ALPMF · Real-Time Price · USD
11.10
0.00 (0.00%)
At close: Aug 08, 2025, 2:03 PM

Astellas Pharma Income Statement

Financials in JPY. Fiscal year is April - March.
Fiscal Year FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Mar 31, 2025 Mar 31, 2024 Mar 31, 2023 Mar 31, 2022 Mar 31, 2021
Revenue
1,912.3B 1,603.7B 1,518.6B 1,296.2B 1,249.5B
Cost of Revenue
349.21B 292.49B 288.35B 253.01B 246.06B
Gross Profit
1,563.1B 1,311.2B 1,230.3B 1,043.2B 1,003.5B
Operating Income
41.04B 25.52B 133.03B 155.69B 136.05B
Interest Income
7.87B 11.46B 8.11B 6.15B 11.61B
Pretax Income
31.24B 24.97B 132.36B 156.89B 145.32B
Net Income
50.75B 17.05B 98.71B 124.09B 120.59B
Selling & General & Admin
843.03B 740.11B 630.27B 548.84B 504.32B
Research & Development
327.65B 294.2B 276.13B 246.01B 224.49B
Other Expenses
351.39B 251.36B n/a n/a n/a
Operating Expenses
1,522.1B 1,285.7B 1,098.7B 912.19B 867.89B
Interest Expense
17.68B 12.01B 8.78B 4.95B 2.33B
Selling & Marketing Expenses
n/a n/a n/a n/a n/a
Cost & Expenses
1,871.3B 1,578.2B 1,387.1B 1,165.2B 1,114B
Income Tax Expense
-19.51B 7.92B 33.65B 32.8B 24.73B
Shares Outstanding (Basic)
1.8B 1.79B 1.82B 1.85B 1.86B
Shares Outstanding (Diluted)
1.8B 1.8B 1.83B 1.85B 1.86B
EPS (Basic)
28.35 9.50 54.24 67.08 64.93
EPS (Diluted)
28.24 9.47 54.09 67.05 64.90
EBITDA
248.05B 194.81B 337.39B 297.83B 323.58B
EBIT
48.91B 36.97B 141.14B 161.84B 147.66B
Depreciation & Amortization
199.13B 157.84B 105.74B 79.68B 72.65B